Skip to content

Observation on the curative effect and mechanism of Qi Jindan in treating unstable angina pectoris of Phlegm-stasis Interjunction Syndrome

Observation on the curative effect and mechanism of Qi Jindan in treating unstable angina pectoris of Phlegm-stasis Interjunction Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001002
Enrollment
Unknown
Registered
2025-05-17
Start date
2024-04-19
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Qijin Dan group:Qijin Dan and standard Western treatment

Sponsors

Wuxi Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1Patients with a confirmed history of myocardial infarction (MI) or coronary angiography/spiral CT-confirmed coronary stenosis =50% and TCM syndrome differentiation consistent with phlegm-stasis obstruction syndrome or qi deficiency with blood stasis syndrome. 2.Stable vital signs and in good general condition. 3.Age =18 years old. 4.Participants must provide informed consent and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients diagnosed with severe cardiac conditions (e.g. malignant arrhythmias structural heart disease) or acute comorbidities such as cerebral infarction (acute phase) or severe respiratory insufficiency. 2.Patients with severe systemic diseases including: Heart failure (severe) Hepatic dysfunction (AST/ALT >1.5× upper limit of normal) Renal impairment (BUN/Cr above upper limit of normal) Hematologic endocrine or severe primary disorders Malignancy gastrointestinal bleeding peptic ulcers or bleeding tendency (if deemed likely to interfere with trial completion). 3Patients with psychiatric disorders cognitive impairment or legal disability. 4.Pregnant/lactating women women planning pregnancy or hypersensitivity to trial drug components. 5.Participation in another clinical trial within the past 3 months or current enrollment. 6.Unwillingness to comply with study procedures.

Design outcomes

Primary

MeasureTime frame
Matrix Metalloproteinase-2;Insulin-like Growth Factor-1;Hypoxia Inducible Factor 1-alpha;

Secondary

MeasureTime frame
TCM syndrome scores;SAQ scores;coronary Gensini scores;

Countries

China

Contacts

Public ContactZhou Yingqi

Wuxi Hospital of Traditional Chinese Medicine

523104179@qq.com18261559817

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026